C. Rahj Robinson

TL;DR: Sulindac reduces the number and size of colorectal adenomas in patients with familial adenomatous polyposis, but its effect is incomplete, and it is unlikely to replace colectomy as primary therapy.

TL;DR: The frequent detection of p53 mutation in the serum of patients with early stage tumors suggests a possible use of this approach for clinical prognosis and cancer monitoring of colorectal cancer patients.

TL;DR: The findings suggest that "aberrant crypt focus" is a generic term analogous to "polyp" and requires further histopathologic, phenotypic, or genotypic classification into dysplastic and heteroplastic types.

TL;DR: A role for prostanoids in progression of colorectalPolyposis in familial adenomatosis polyposis patients patients is suggested, and the relative levels of three prostanoid were elevated in adenomas compared to normal-appearing mucosa from the same patients, andThe resulting ratios were correlated with the size of the adenoma.

TL;DR: Sulindac treatment, at drug doses shown to regress colorectal adenomas in FAP patients, has heterogeneous effects on the level of major prostaglandins in their rectal mucosa and may not prevent coloreCTal cancer due to uncoupling ofprostaglandin levels and carcinogenesis.